GlassScriptPhysician profile
Alyssa Bruns
NPI 1841815230
$613.33
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $572 · 2022: $41.70.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $156.65 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $153.19 | 2021 | |
| Lucid Diagnostics INC. | $97.34 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.34 | 2021-2022 | |
| Daiichi Sankyo INC. | $24.64 | 2021 | |
| Abbvie INC. | $21.35 | 2021 | |
| Esperion Therapeutics, INC. | $17.98 | 2021 | |
| Uswm, LLC | $17.85 | 2021 | |
| Eisai INC. | $17.29 | 2021 | |
| Pfizer INC. | $16.56 | 2021 | |
| Alfasigma USA, INC. | $15.82 | 2021 | |
| Medtronic, INC. | $14.61 | 2021 | |
| Acerus Pharmaceuticals Corporation | $11.71 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Bruns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.